16
7
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T3141 |
Bendazac L-lysine
Bendazac lysine,Bendazaco lisina,苄达赖氨酸 |
Others | Others |
Bendazac L-lysine (Bendazaco lisina) 是一种能够控制白内障的药物。它可以保护患者的视力水平,延缓手术干预的需要。 | |||
TP1501L |
CTTHWGFTLC, CYCLIC acetate(244082-19-7 free base)
|
MMP | Proteases/Proteasome |
CTTHWGFTLC, CYCLIC acetate(244082-19-7 free base) 是基质金属蛋白酶 (MMP)-2 和 MMP-9 的抑制剂。它也被称为IV 型胶原酶或明胶酶。明胶酶是癌症治疗干预的潜在靶点,这些酶的抑制剂可以防止肿瘤进展。 | |||
T14978 |
CL-82198
|
MMP | Proteases/Proteasome |
CL-82198 是 MMP-13选择性抑制剂。它能够与 MMP-13 的整个 S1' 口袋结合,这是其对 MMP-13 选择性和对其他 MMP 缺乏抑制活性的基础。它可用于研究骨关节炎。 | |||
T61354 |
Fosphenytoin
|
Others | Others |
Fosphenytoin 是一种磷酸酯前药,可替代静脉注射苯妥英,用于急性干预癫痫发作。Fosphenytoin 在肠胃外给药可水解成具有抗惊厥作用的苯妥英。Fosphenytoin 可用于多种给药方式,如静脉注射和腹腔注射。 | |||
T22323 |
Enoxaparin sodium
|
Thrombin | Proteases/Proteasome |
Enoxaparin sodium 是一种低分子量肝素 (LMWH),已获得美国 FDA 批准,可用于医疗管理的 ST 段心肌梗死 (STEMI) 或 STEMI 及随后的经皮冠状动脉介入治疗 (PCI) 患者。它与抗凝血酶结合并增强其作用,并抑制凝血因子 XIa、IXa、Xa 和 IIa(凝血酶),从而防止血栓形成。 | |||
T22232 |
Alfuzosin
|
||
Alfuzosin 是选择性和竞争性的α1肾上腺素受体拮抗剂,可用于良性前列腺增生(BPH)的研究。 | |||
T70614 |
SLR080811 HCl
|
||
SLR080811 is a SphK inhibitor. Sphingosine-1-phosphate (S1P) is a ubiquitous, endogenous small molecule that is synthesized by two isoforms of sphingosine kinase (SphK1 and 2). Intervention of the S1P signaling pathway has attracted significant attention because alteration of S1P levels is linked to several disease states including cancer, fibrosis, and sickle cell disease. | |||
TP1501 |
CTTHWGFTLC, CYCLIC
|
||
This cyclic CTT Gelatinase Inhibitor peptide is an inhibitor for matrix metalloproteinases (MMP)-2 and MMP-9. It is also called type IV collagenase or gelatinase. Gelatinases are potential targets of therapeutic intervention in cancer, and inhibitors of t | |||
TP1674 |
HIV p17 Gag (77-85)
HIV p17 Gag 77-85 |
||
HIV p17 Gag (77-85) is an attractive target for molecular intervention, because it is involved in the viral replication cycle at both the pre- and postintegration levels. In the present experiments, we targeted p17 by intracellularly expressing a cDNA enc | |||
T69822 |
Ritlecitinib tosylate
|
||
Ritlecitinib, also known as PF-06651600, is a potent and selective JAK3 inhibitor. PF-06651600 is a potent and low clearance compound with demonstrated in vivo efficacy. The favorable efficacy and safety profile of this JAK3-specific inhibitor PF-06651600 led to its evaluation in several human clinical studies. JAK3 was among the first of the JAKs targeted for therapeutic intervention due to the strong validation provided by human SCID patients displaying JAK3 deficiencies. | |||
T40341 | SARS-CoV-2-IN-11 | ||
SARS-CoV-2-IN-11 is a highly potent and non-toxic inhibitor of the 3C-like protease (3CLpro) of SARS-CoV-2, demonstrating IC50 and EC50 values of 0.17 nM and 1.45 nM, respectively. This compound targets the essential viral replication enzyme, 3CLpro, making it an attractive candidate for intervention strategies. SARS-CoV-2-IN-11 holds significant promise in the development of specific antivirals against SARS-CoV-2. | |||
T70613 |
SLP120701 HCl
|
||
SLP120701 is a potent and selective sphingosine kinase 2 inhibitor. Sphingosine-1-phosphate (S1P) is a ubiquitous, endogenous small molecule that is synthesized by two isoforms of sphingosine kinase (SphK1 and 2). Intervention of the S1P signaling pathway has attracted significant attention because alteration of S1P levels is linked to several disease states including cancer, fibrosis, and sickle cell disease. | |||
T71275 | CID16725315 | ||
Thiocarbazate, also known as CID16725315, is an inhibitor of human cathepsin L. Inhibition of cathepsin L thus holds promise for therapeutic intervention for both SARS-CoV and Ebola virus infection. With respect to the development of antiviral agents, inhibitors of human cathepsin L are not subject to resistance because of rapid mutations of the viral genome. Cathepsin L is therefore an attractive target for drug development. | |||
T40340 |
SARS-CoV-2-IN-10
|
||
SARS-CoV-2-IN-10 is a powerful and non-toxic inhibitor of SARS-CoV-2 3CL protease, with IC50 and EC50 values of 0.13 nM and 1.03 nM, respectively. The SARS-CoV-2 3C-like protease (3CLpro) is a critical enzyme for viral replication and serves as an ideal target for intervention. By targeting the SARS-CoV-2 3CL protease, SARS-CoV-2-IN-10 has the potential to facilitate the development of effective antiviral drugs specific to SARS-CoV-2. | |||
T70900 | VT-ME6 | ||
VT-ME6 is a potent and selective sphingosine kinase 2 inhibitor. VT-ME6, contained a quaternary ammonium group as a warhead and established that a positively charged moiety is necessary for engaging key amino acid residues in the enzyme binding pocket.13,14 This compound is moderately potent (Ki = 8 lM) and displays three-fold selectivity for SphK2 over SphK1. Sphingosine-1-phosphate (S1P) is a ubiquitous, endogenous small molecule that is synthesized by two isoforms of sphingosine kinase (SphK... | |||
T71618 | Oxocarbazate | ||
Oxocarbazate, also known as CID23631927, is an inhibitor of human cathepsin L. In the cathepsin L inhibition assay, The oxocarbazate caused a time-dependent 17-fold drop in IC50 from 6.9 nM (no preincubation) to 0.4 nM (4-h preincubation). Slowly reversible inhibition was demonstrated in a dilution assay. CID23631927 demonstrate activity in blocking both SARS-CoV (IC50 = 273 nM) and Ebola virus (IC50 = 193 nM) entry into human embryonic. CID 23631927 was a subnanomolar, slow-binding, reversible... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
PDK0101 |
4-Methylcinnamic acid
对甲基肉桂酸,对甲基肉桂 |
Antifungal | Microbiology/Virology |
4-Methylcinnamic acid 是一种肉桂酸类似物,可用作克服抗真菌耐受性的干预催化剂。它可提高细胞壁破坏剂的效力。 | |||
T5646 |
Cinnamic acid
3-Phenylacrylic acid,β-Phenylacrylic acid,肉桂酸 |
Endogenous Metabolite | Metabolism |
Cinnamic acid (β-Phenylacrylic acid) 在癌症干预中具有潜在的应用价值,对胶质母细胞瘤,黑色素瘤,前列腺癌,肺癌细胞的IC50=1-4.5 mM。 | |||
T3S0738 |
yangonin
Y100550,甲氧醉椒素 |
Cannabinoid Receptor; NF-κB; Autophagy | Autophagy; GPCR/G Protein; NF-κB |
Yangonin (Y100550) 是一种新型 CB1 受体配体,对人重组 CB1 受体具有亲和力。它可能是干预 NF-κB 依赖性病理状况的候选药物。 | |||
T6S1966 |
Curculigoside
Curculigoside A,仙茅苷 |
Antioxidant; NF-κB; JAK; STAT | Angiogenesis; Chromatin/Epigenetic; JAK/STAT signaling; NF-κB; oxidation-reduction; Stem Cells |
Curculigoside (Curculigoside A) 是仙茅中的主要皂苷,具有显著的抗氧化、抗骨质疏松、抗抑郁和神经保护作用。它通过调节JAK/STAT/NF-κB 信号传导途径,具有抗关节炎作用。 | |||
TN1042 |
Chebulic acid
|
Others | Others |
Chebulic acid 是一种分离自Terminalia chebula 中的酚羧酸化合物,具有显著的抗氧化作用,它能够打破由晚期糖基化终产物 (AGEs) 诱导的蛋白质交联,阻碍 AGEs 的形成。它能够有效控制代谢参数升高、氧化应激和肾损害,支持其在糖尿病肾病中的有益作用。 | |||
T6S0525 |
Farrerol
|
ERK; p38 MAPK; Akt | Cytoskeletal Signaling; MAPK; PI3K/Akt/mTOR signaling |
Farrerol 是一种杜鹃花的生物活性成分,具有抗氧化、抗肿瘤、抗炎、神经保护和肝保护等多种功能。 | |||
TN5097 |
Tanshindiol C
|
LDL; Histone Methyltransferase | Chromatin/Epigenetic; Metabolism |
Tanshindiol C protects macrophages from oxLDL induced foam cell formation via activation of Prdx1/ABCA1 signaling and that Prdx1 may be a novel target for therapeutic intervention of atherosclerosis.It possesses a unique anti-cancer activity whose mechani |